NorthView Acquisition, a blank check company targeting small cap healthcare businesses in North America, Europe, and APAC, lowered the proposed deal size for its upcoming IPO on Tuesday.
The New York, NY-based company now plans to raise $150 million by offering 15 million units at $10. The company had previously filed to offer 18 million units at the same price. Each unit now consists of one share of common stock, one right to receive one-tenth of a share upon the completion of an initial business combination, and one-half of a warrant, exercisable at $11.50. At the revised deal size, NorthView Acquisition will raise -17% less in proceeds than previously anticipated.
The company was formed by CEO and Director Jack Stover, whose former roles include serving as CEO of Interpace Biosciences and Antares Pharma, and CFO and Director Fred Knechtel, who previously served as the CFO of Interpace and GENEWIZ. The company plans to target small cap businesses domiciled in North America, Europe and/or the APAC regions that are developing assets in the biopharmaceutical, medical technology/medical device, and diagnostics spaces.
NorthView Acquisition was founded in 2021 and plans to list on the Nasdaq under the symbol NVACU. I-Bankers Securities is the sole bookrunner on the deal.
